Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Infusion reaction" patented technology

(See "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy" and "Cutaneous side effects of conventional chemotherapy agents".) CHARACTERISTICS OF REACTIONS. Signs and symptoms of infusion reactions — Infusion reactions may affect any organ system in the body. Most are mild in severity, although severe and ...

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

ActiveUS20260023073A1Peptide/protein ingredientsSkeletal disorderSerum uric acidAntiendomysial antibodies
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
View all
Owner:HORIZON THERAPEUTICS USA INC

Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

ActiveUS20260118349A1Peptide/protein ingredientsSkeletal disorderAntiendomysial antibodiesIntravenous IG
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
View all
Owner:HORIZON THERAPEUTICS USA INC

Combination therapies of prednisone and uricase molecules and uses thereof

ActiveUS12496331B2Organic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesPrednisonum
Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and / or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.
Combination therapies of prednisone and uricase molecules and uses thereof
Combination therapies of prednisone and uricase molecules and uses thereof
Combination therapies of prednisone and uricase molecules and uses thereof
View all
Owner:HORIZON THERAPEUTICS USA INC

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

ActiveUS12560596B2Peptide/protein ingredientsSkeletal disorderAntiendomysial antibodiesIntravenous IG
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
View all
Owner:HORIZON THERAPEUTICS USA INC

Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

ActiveUS12669498B2Antiendomysial antibodiesIntravenous IG
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
View all
Owner:HORIZON THERAPEUTICS USA INC